COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 2 for:    kcc peptide
Previous Study | Return to List | Next Study

Study of KCC Peptide Application in the Colon (KCC 1B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02156557
Recruitment Status : Completed
First Posted : June 5, 2014
Last Update Posted : April 4, 2017
Olympus Corporation
Information provided by (Responsible Party):
Danielle Kim Turgeon, University of Michigan

Brief Summary:

We are studying new ways to look for abnormal areas/tissues of the colon during a colonoscopy. The current scopes used for colonoscopies are very good. But if the area doesn't look different to the naked eye, then the scope can't improve on that. We are using special stains or dyes and special scopes to see abnormal areas that are hard to see with the naked eye. The stain or dye is "fluorescent", meaning it glows when special light is used in the colonoscopy scope.

You are being asked to let us spray a peptide with a fluorescent tag onto your colon. Peptides are small chains of amino acids (the building blocks that make up proteins) linked together. The peptide we use has 7 amino acids attached to a fluorescent tag ("FIT C" or Fluoresceinisothiocyanate). FITC is used by eye doctors to examine your eyes (the yellow eye drops).

We are testing this "fluorescent peptide" to see if it will stick if there are any abnormal areas. If the peptide "sticks", it will "glow" when a special light in the scope is used. In this study, we will apply the fluorescent peptide to your colon by using a spray tube that fits in the colonoscope.

This is a phase IB study. This means that although we have applied the peptide to 25 people in our first research study, we still need to learn more about "fluorescent peptide" in people. The Food and Drug Administration (FDA) has not approved this agent, but is allowing us to test it in this study. The main goal of this study is to see if the peptide "glows" well and if we can take pictures of areas that do glow.

This is a research study of the peptide and our ability to see it "glow or fluoresce". Being in this study and applying the peptide won't change how our biopsies are taken or how your colonoscopy is done.

Condition or disease Intervention/treatment Phase
Colon Polyps Colorectal Cancer Inflammatory Bowel Disease (IBD) Biological: Colon KCC Heptapeptide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Phase 1B Study of KCC Peptide Application in the Colon
Study Start Date : June 2014
Actual Primary Completion Date : July 2016
Actual Study Completion Date : August 2016

Arm Intervention/treatment
Experimental: peptide application

Investigational Agent Administration

  • 1.2 mg lyophilized powder per single-use amber vial
  • Lyophilized powder reconstituted with 10 mL of 0.9% NaCl
  • Final concentration of 76.4 μM for single, one-time topical application
  • The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
Biological: Colon KCC Heptapeptide
  • Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.
  • The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then "injected" into a special, single-use "sprayer", like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.
  • The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.
  • We will obtain copies of your endoscopy report and any pathology reports.

Primary Outcome Measures :
  1. Validation of binding of peptide [ Time Frame: One time during colonoscopy ]
    The peptide will be applied during colonoscopy to areas that appear abnormal with white light endoscopy. The peptide fluorescence will be assessed via imaging to assess specificity of binding as compared to standard of care pathology interpretation of tissue.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects felt to be at increased risk for CRC and colonic polyps


-Subjects with known colonic adenomas scheduled for colonic resection


  • Subjects who are scheduled for outpatient colonoscopy for follow up surveillance of IBD with known dysplasia or who are at high risk for high grade dysplasia.
  • Subjects who are scheduled for outpatient colonoscopy in the medical procedures unit at the University of Michigan Health Center
  • All subjects who are medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) who meet the inclusion/exclusion criteria will be included. Standard practice guidelines for safely proceeding with the procedure will be sufficient for our study
  • Adults aged 18 to 100 years
  • Willing and able to sign informed consent
  • The effects of Colon KCC Heptapeptide (5-FITC-labeled peptide) on the developing human fetus are unknown. For this reason, women of childbearing potential must have a negative pregnancy test on the day of the procedure prior to receiving the Colon KCC Heptapeptide (5-FITC-labeled peptide agent) or be post-menopausal. Post-menopausal women are defined as post-hysterectomy, or over 40 and at least 18 months without menses and not on birth-control.

Exclusion Criteria:

  • Subjects with known allergy or negative reaction to fluorescein or derivatives.
  • Subjects on active chemotherapy or radiation treatment
  • Pregnant or trying to conceive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02156557

Layout table for location information
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
Danielle Kim Turgeon
Olympus Corporation
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Danielle Kim Turgeon, Professor of Internal Medicine, University of Michigan Identifier: NCT02156557    
Other Study ID Numbers: HUM00086259
First Posted: June 5, 2014    Key Record Dates
Last Update Posted: April 4, 2017
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammatory Bowel Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases